PCV43 CLINICAL AND ECONOMIC IMPACT OF BIVALIRUDIN ON BLEEDING EVENTS IN HIGH RISK UNSTABLE ANGINA (UA)/NON-ST-ELEVATION MYOCARDIAL INFARCTION (NSTEMI) PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION (PCI) IN FRANCE

  • Olchanski N
  • Slawsky K
  • Cyr P
  • et al.
N/ACitations
Citations of this article
5Readers
Mendeley users who have this article in their library.

Abstract

OBJECTIVES: Approximately 140,000 percutaneous coronary interventions (PCIs) will be performed in France in 2009/2010. PCI complications often increase resource utilization. New antithrombotic therapies have the potential to improve outcomes and decrease costs. The ACUITY trial demonstrated a decreased mortality and a statistically significant reduction in bleeding events with bivalirudin as compared to a heparin-plus-GPI (HEP+GPI) regimen. This analysis evaluated the economic impact of this improvement in the French hospital setting with a focus on reduced access site- and non-access site-related bleeding events. METHODS: A budget-impact model was developed to evaluate the impact of bivalirudin in high-risk (per ESC definition) UA/NSTEMI patients undergoing PCI in a French hospital. Clinical data for the model were derived from the ACUITY trial and included 30-day event rates for major complications (total and non-access site bleeding, Q-wave myocardial infarction, repeat PCI and coronary artery bypass graft). Economic data were derived from French medical literature, including clinical event costs, ward costs (both regular and ICU/ CCU) and pharmaceutical costs. RESULTS: In 100 PCI patients, bivalirudin use would result in 4 fewer protocol-defined major bleeding events (3.8%) and 12 fewer minor bleeding events (12.2%). Considering non-access site bleeding events only (all bleeds excluding retroperitoneal and access site bleeds), bivalirudin use would reduce major and minor bleeding events by 0.7% and 4.7%, respectively. Including all bleeding events, the total hospital budget impact of treating 100 high risk UA/NSTEMI patients using a HEP+GPI-based strategy is 3626,903. Introducing a bivalirudin-based strategy could save 332,520 (5%). The reduction in non-access site bleeding events alone could result in savings of 318,028 (3%) per 100 patients. CONCLUSIONS: A bivalirudinbased strategy for anticoagulant use in high risk UA/NSTEMI patients undergoing PCI is associated with favorable clinical and economic outcomes when compared with HEP+GPI in a French hospital setting.

Cite

CITATION STYLE

APA

Olchanski, N., Slawsky, K., Cyr, P., Schwenkglenks, M., & Steinhubl, S. (2010). PCV43 CLINICAL AND ECONOMIC IMPACT OF BIVALIRUDIN ON BLEEDING EVENTS IN HIGH RISK UNSTABLE ANGINA (UA)/NON-ST-ELEVATION MYOCARDIAL INFARCTION (NSTEMI) PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION (PCI) IN FRANCE. Value in Health, 13(3), A157. https://doi.org/10.1016/s1098-3015(10)72763-7

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free